|
|
|
|
|
by kileywm
1130 days ago
|
|
Very interesting document; however, the text seems to disagree with your adderall explanation. https://www.federalregister.gov/d/2022-26351/p-16 > According to DEA's data, manufacturers have not fully utilized the APQ for amphetamine in support of domestic manufacturing, reserve stocks, and export requirements for the past three calendar years 2020, 2021 and 2022. > Based on this trend, DEA has not implemented an increase to the APQ for amphetamine at this time. Which suggests that the DEA's quota for adderall is not (yet) to blame. |
|
“The majority” “legitimate patient medical needs” sounds like a bunch of trippy legalese. If it’s the majority of the manufacturers they contacted, doesn’t that mean that there’s at least one that has exhausted their production? Could that one perhaps be the largest one, like Teva?
If that’s the case, then yes, there could be a shortage. And they’re not increasing it because there’s been a surge of “illegitimate” shops that have popped up and prescribed remotely since Covid that the DEA is investigating and/or shutting down.
And that may not even be the real reason. Could be the understaffing issues quoted in august. Either way, that answer from the register is a non-answer.